Med. praxi. 2011;8(3):119-122

Endothelial dysfunction - the first stage of atherosclerosis

MUDr.Michal Vrablík, Ph.D., Michaela Janotová, MUDr.Eva Motyková, MUDr.Martina Prusíková
III. interní klinika 1. LF UK a VFN, Praha

Endothelial cells are not only a mechanical barrier but also form metabolically very active tissue regulating vascular tone, permeability

and other vascular functions. Functional impairment of endothelial layer (endothelial dysfunction) initiated by a number of mechanical,

physical, chemical and immunological factors, is the beginning of vascular changes, which might result in atherotrombotic complications.

Endothelial dysfunction can be assessed by various methods, however, these are not being routinely used in clinical practice as they yield

widely variable results. Nevertheless, the methods help us understand the mechanisms, through which both non- and pharmacological

treatments induce restitution of endothelial function and, thus, reduce risk of development of subsequent stages of atherosclerosis.

Keywords: endothelial dysfunction, atherosclerosis, cardiovascular disease, erectile dysfunction, prevention

Published: March 23, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M, Janotová M, Motyková E, Prusíková M. Endothelial dysfunction - the first stage of atherosclerosis. Med. praxi. 2011;8(3):119-122.
Download citation

References

  1. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976; 193: 1094-1100. Go to original source... Go to PubMed...
  2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362(6423): 801-809.
  3. Ross R. Atherosclerosis-an inflammatory disease? N Engl J Med 1999; 340(2): 115-125. Go to original source... Go to PubMed...
  4. Hansson GK, Jonasson L, Seifert PS, Stemme S. Imunne mechanisms in atherosclerosis. Atherosclerosis 1989; 9: 567-578. Go to original source...
  5. Malík J, Melenovský V, Wichterle D. Funkce a dysfunkce endotelu. Cas Lek Ces 2000; 139(7): 197-202.
  6. Santoro D, Bellinghieri G, Conti G, Pazzano D, Satta E, Costantino G, SavicaV. Endothelial dysfunction in chronic renal failure. J Ren Nutr. 2010; 20(Suppl 5): S103-108. Go to original source... Go to PubMed...
  7. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis, Circulation, 2002; 105: 2-4. Go to original source...
  8. Gurfinkel E, Bozovich A, Daroca A. Randomised trial of roxithromycin in non Q wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-407. Go to original source... Go to PubMed...
  9. Foresta C, Caretta N. Penile duplex pharmaco-ultrasonography of cavernous arteries in men with erectile dysfunction and generalized atherosclerosis; Int J Androl; 2006; 29(4): 496-501. Go to original source... Go to PubMed...
  10. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005; 59: 225-229. Go to original source... Go to PubMed...
  11. Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, Montorsi P, Montorsi F, Vlachopoulos C, Kloner R, Sharlip I, Miner M. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010; 64(7): 848-857. Go to original source... Go to PubMed...
  12. Cohn JN, Wilson DJ, Neutel J, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137-144. Go to original source... Go to PubMed...
  13. Jamerson K, Bakris GL, Dahlof B, et al. For the ACCOMPLISH Investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
  14. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.